In Vivo Osteoarthritis Target Validation Utilizing Genetically-Modified Mice
The DOI matches its Crossref record.
Abstract
Osteoarthritis (OA) is a progressive disease of cartilage degradation that significantly impacts quality of life. There are currently no effective treatments and, while a large number of potential therapeutic targets exist, most have not been validated in vivo. The range of OA models in the mouse has dramatically expanded in the last decade, beyond spontaneous models, to include genetically modified transgenic, knockout (KO) and knock-in (KI) mice that can develop premature cartilage degeneration reminiscent of OA. In addition, instability models of OA, either induced by intra-articular (IA) collagenase or surgery, are providing a set of tools to assist in the identification of disease-modifying OA drug (DMOAD) targets. These models are now vital tools to dissect the pathways essential to the pathogenesis of OA. Two targets, ADAMTS (a disintegrin and metalloproteinase with thrombospondin-like motifs)-5 and IL-1beta (interleukin-1 beta), have been validated in the surgical destabilization of the medial meniscus model (DMM) in KO mice. Other potential targets evaluated in instability models, either showed no disease modification or a worsening of disease, suggesting that those targets have no role, a protective role or that other, more destructive enzymes etc., can overcompensate. Development of small molecule or protein antagonist inhibitors of therapeutic targets require many years to bring to clinical trials and often confront potency and safety issues which impede successful progress. Validation, or confirmation of therapeutic targets in vivo is most clearly and efficiently obtained by using KO studies, than by creating potent and selective DMOADs to multiple potential targets. While the results in the mouse will not always transpose to the human condition, the track record of mouse knockouts corresponding to the human phenotype have been excellent. These results indicate that the evaluation of genetically modified mice will become increasingly important as we unravel the genes contributing to OA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Robinson, W. H., Lepus, C. M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T. M., & Sokolove, J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.136 · Cited by 1,438
Goldring, M. B., & Goldring, S. R. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21258 · Cited by 1,179
Oxidative stress and inflammation in osteoarthritis pathogenesis: Role of polyphenols
Ansari, M. Y., Ahmad, N., & Haqqi, T. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110452 · Cited by 709
Animal Models of Osteoarthritis: Comparisons and Key Considerations
McCoy, A. M. (2015) · Veterinary Pathology · doi:10.1177/0300985815588611 · Cited by 651
Proteases involved in cartilage matrix degradation in osteoarthritis
Troeberg, L., & Nagase, H. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.06.020 · Cited by 579
Metadata
- Authors
- Glasson, S.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 367-376
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2088657142
- Cited by
- 144
- References
- 0
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vivo Osteoarthritis Target Validation Utilizing Genetically-Modified Mice. https://app.cochat.ai/papers/10.2174/138945007779940061
- The paper
- Glasson, S. (2007). In Vivo Osteoarthritis Target Validation Utilizing Genetically-Modified Mice. Current Drug Targets. https://doi.org/10.2174/138945007779940061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.